David G. Maloney, MD, PhD
Provider Profile: Dr. David G. Maloney
Dr. David G. Maloney is a hematology oncologist at Seattle Cancer Care Alliance and an associate professor of Medicine in the Division of Oncology at the University of Washington School of Medicine.
“Lymphoma and myeloma treatments are rapidly evolving,” says Dr. Maloney. “Tumor vaccines and monoclonal antibodies are providing new treatment options. These can be properly integrated with consideration of the patient's clinical situation and personal philosophy.”
Dr. Maloney treats patients who have chronic lymphocytic leukemia, lymphoma, or multiple myeloma. His clinical expertise is with antibodies, vaccines, and bone marrow transplantation for treatment of these malignancies.
“After studying many of the sciences, I was especially interested in biology,” says Dr. Maloney, “which led to medicine. I was fortunate to do research with Dr. Ron Levy at Stanford University in the early use of monoclonal antibodies to treat lymphoma. I wanted to continue this and chose oncology.”
Dr. Maloney grew up in Yakima, Washington and earned a Ph.D. and a medical degree from Stanford University. He joined the University of Washington and Fred Hutchinson Cancer Research Center in 1994 and is happy to be back in the Pacific Northwest.
“I enjoy helping patients deal with cancer,” Dr. Maloney says, “and the research and application of new treatments for chronic lymphocytic leukemia, non-Hodgkin’s lymphoma, and multiple myeloma. In my lifetime, I hope to see continued improvement in cancer treatment.”
When he isn’t caring for his patients, Dr. Maloney likes to spend time with his family, as well as hiking, fishing, and bird watching. He also enjoys wood working and bird photography.
David G. Maloney, MD, PhDDr. Maloney applies the latest research on new treatments when treating his patients for chronic lymphocytic leukemia, non-Hodgkin’s lymphoma, and multiple myeloma. Read more about Dr. Maloney and his work at SCCA.
Patient Care Philosophy:
Lymphoma and myeloma treatments are rapidly evolving, with tumor vaccines and monoclonal antibodies providing new treatment options. These can be properly integrated with consideration of the patient's clinical situation and personal philosophy.
- Member, Clinical Research Division, Fred Hutchinson Cancer Research Center
- Professor, Medical Oncology Division, University of Washington School of Medicine
Antibodies, Vaccines and Transplantation for Lymphoma and Myeloma
Education And Training
- PhD: Stanford University, 1991
- MD: Stanford University, Medicine, 1985
- BS: Whitworth College, 1977
- Dr. Maloney was recognized as a 2012 "Top Doctor" in Seattle Magazine's 2012 annual survey.
- Autologous Stem Cell Transplant Followed By Donor Stem Cell Transplant In Treating Patients With Relapsed or Refractory Lymphoma (FH 1409)
- Ofatumumab vs. Rituximab for Relapsed Follicular Lymphoma (FH 2522)